Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
about
A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis.Cognitive Rehabilitation for Attention and Memory in people with Multiple Sclerosis: study protocol for a randomised controlled trial (CRAMMS).Mapping the neck disability index to SF-6D in patients with chronic neck painImpact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple SclerosisStatistical Alchemy: Conceptual Validity and Mapping to Generate Health State Utility Values.Mapping MOS-HIV to HUI3 and EQ-5D-3L in Patients With HIV
P2860
Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Using the Multiple Sclerosis I ...... 2, to the EQ-5D and the SF-6D.
@en
Using the Multiple Sclerosis I ...... 2, to the EQ-5D and the SF-6D.
@nl
type
label
Using the Multiple Sclerosis I ...... 2, to the EQ-5D and the SF-6D.
@en
Using the Multiple Sclerosis I ...... 2, to the EQ-5D and the SF-6D.
@nl
prefLabel
Using the Multiple Sclerosis I ...... 2, to the EQ-5D and the SF-6D.
@en
Using the Multiple Sclerosis I ...... 2, to the EQ-5D and the SF-6D.
@nl
P2093
P1433
P1476
Using the Multiple Sclerosis I ...... 2, to the EQ-5D and the SF-6D
@en
P2093
Claire Telford
Colin Green
Dave Wright
John Zajicek
P304
P356
10.1016/J.JVAL.2012.07.007
P577
2012-11-04T00:00:00Z